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ABSTRACT 
A simple, accurate and precise spectroscopic method was developed for simultaneous estimation of Irbesartan and atorvastatin in synthetic mixture 
usingsimultaneous eqution Method.In this spectroscopic  method, 226.00 nm and 246.00 nm wavelengths  were selectedfor measurement of 
absorptivity. Both the drugs show linearity in a concentration range of 05-30 μg/ml at theirrespective λmax. Accuracy, precision and recovery 
studies were done by QC samplescovering lower, medium and high concentrations of the linearity range. The relative standard deviation for 
accuracy,precision studies were found to be within the acceptance range (<2%). The limit of determination was 0.033μg/ml and 0.125 μg/ml for 
Irbesartan and atorvastatin, respectively. The limit of quantification was 0.1008 μg/ml and 0.3792 μg/ml for Irbesartan and atorvastatin, 
respectively. Recovery of Irbesartan and atorvastatin were found to be 99.75 % and 99.52% respectively confirming the accuracy of the proposed 
method. The proposed method is recommended for routine analysis since they are rapid,simple, accurate and also sensitive and specific by no 
heating and no organic solvent extraction. 
Keywords: Irbesartan, atorvastatin, simultaneous estimation, Simultaneous equation method, analysis method. 
 
INTRODUCTION 
Irbesartan, an angiotensin II receptor antagonist [1].Is used mainly 
for the treatment of hypertension. It is an orally active 
nonpeptidetetrazole derivative and selectively inhibits angiotensin 
II receptor type 2. Angiotensin II receptor type1 antagonists have 
been widely used in treatment of diseases like hypertension, heart  
Irbesartan is white or almost white, crystalline powder. Solubility is 
given in practically insoluble in water, sparingly soluble in methanol, 
slightly soluble in methylene chloride. 
 
 
Fig.:1  Structure of Irbesartan[3] 
Atorvastatin is used as lipid-lowering agents used in 
hyperlipidaemia condition.Atorvastatin selectively and 
competitively inhibits the hepatic enzyme HMG-CoA reductase.(4) 
As HMG-CoA reductase is responsible for converting HMG-CoA to 
mevalonate in the cholesterol biosynthesis pathway, this results in a 
subsequent decrease in hepatic cholesterol levels and decreases 
blood cholesterol level. 
Atorvastatin 
iswhiteoralmostwhite,crystallinepowder.Solubilityisgiveninpractical
ly insoluble in water, soluble in methanol, slightlysolublein 
methylenechloride. 
failure, myocardial infarction and diabetic nephropathy. IUPAN 





Fig. 2: Structureofatorvastatin(5) 
Hypertension frequently coexists with hyperlipidaemia and both are 
considered to be major risk factors for developing cardiac disease 
ultimately resulting in adverse cardiac events. This clustering of risk 
factors is potentially due to a common mechanism. Further, patient 
compliance with the management of hypertension is generally better 
than patient compliance with hyperlipidaemia. It would therefore be 
advantageous for patients to have a single therapy which treats both 
of these conditions with help of fixed dose combination of Irbesartan 
and atorvastatin.(6,7) 
The review of literature regarding quantitative analysis of 
Irbesartan and atorvastatinrevealed that no attempt was made to 
develop analytical methods for Irbesartan and atorvastatin. Some 
spectrometric methods and chromatographic methods have been 
reported for theestimation of the individual drugs.The focus of the 
present study was to develop and validate a rapid, stable, specific, 
and economic spectroscopic method for the estimation of Irbesartan 
and atorvastatinin Synthetic mixture.(8,9) 
MATERIALS AND METHODOLOGY 
Atorvastatin and Irbesartan were obtained as gift samples from S 
Kant pharmaceuticals and CTX life science Surat. Synthetic Mixture 
contain 20mg of Atorvastatin and 160mg of Irbesartan. 
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 A double beam UV/Visible spectrophotometer (Shimadzu 
model 2450, Japan) with spectral width of 2 nm, 1 cm quartz 
cells was used to measure absorbance of all the solutions.  
 Spectra were automatically obtained by UV-Probe system 
software. 
 An analytical balance (Sartorius CD2250, Gottingen, Germany) 
was used for weighing the samples.  
 Sonicator(D120/2H, TRANS-O-SONIC) 
 Class ‘A’ volumetric glassware were used (Borosillicte) 
Standard solutionofIrbesartan  (IRB) 
Preparation of stock solution of IRB 
Accurately weighed quantity of Irbesartan 10 mg was transferred to 
100 ml volumetric flask, dissolved and diluted up to mark with 
methanol to give a stock solution having strength of 100μg/ml. 
Preparation of stock solution of ATR 
Accurately weighed quantity of Atorvastatin 10mg was transferred 
to 100 ml volumetric flask, dissolved and diluted up to mark with 
methanol to give a stock solution having strength of 100μg/ml. 
Preparation of standard mixture solution 
From the stock solution of IRB take 1.6ml and from stock solution of 
ATR take 0.2ml and transferred in to 10ml volumetric flask and 
diluted up to mark with methanol to give a solution having strength 
of IRB was 16 μg/ml and ATR was 2μg/ml. 
Preparation of test solution 
From the stock solution of IRB take 1.6ml and from stock solution of 
ATR take 0.2ml and transferred in to 10ml volumetric flask and 
diluted up to mark with methanol to give a solution having strength 
of IRB was 16 μg/ml and ATR was 2μg/ml. 
alibration curves for Irbesartan   
 
Pipette out 0.5, 1.0, 1.5, 2.0, 2.5 and 3.0 ml of the stock solution of 
Irbesartan and atorvastatin (100μg/ml) into a series of 10ml 
volumetric flasks and the volume was adjusted to mark with 
methanol and measured absorbance at 226.00nm and 246nm. Plotte 
the graph of absorbance versus respective concentration of 
Irbesartan and atorvastatin. Linearityrange of IRB and ATR was 
found with correlation co-efficient. 
DEVELOPMENT AND VALIDATION OF SPECTROSCOPIC 
SIMULTANEOUS EQUATION METHOD 
SELECTION OFWAVELENGTHAND METHOD DEVELOPMENT 






Fig.3 Overlainzero orderspectra ofIRB andATR(8:1) ratios, 
respectively 
 




(μg/ml) Absorbance* (226.00nm)±SD IRB Absorbance* (246.00nm)±SD ATR 
IRB ATR 
1 05 05 0.3708±0.0023 0.2672±0.0015 
2 10 10 0.7460±0.0020 0.5674±0.0017 
3 15 15 1.2171±0.0013 0.8872±0.0018 






6 30 30 2.7653±0.0025 1.8772±0.0016 
VALIDATION PARAMETERS(10) 
Linearity andRange 
TheZero order(fig.3)showedlinearabsorbanceat 22 6 . 00 




and ATR, respectively. 
Thismethodobeyedbeer’slawintheconcentrationrange05 - 




d to be 0.9994 and 0.9993,respectively(figure4and 5) 
Theregression line equation forIRB and ATR are as following, 
y = 0.0983x - 0.2385 for IRB _____________ (1) 







Fig.4CalibrationcurveforIRB at 226.00 nm 
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The precision of the developed method was assessed by analyzing 
combined standard solution containing three different 
concentrations  05, 15, 30  μg/ml  for IRB and 05, 15, 30  μg/ml  ATR. 
Three replicate (n=3) each on same day. Intraday precision data 




Table 2 Intraday precision data for estimation ofIRB andATR*(n=3) 
Conc. (μg/ml) 
 
IRB Abs.* ± % RSD ±% RSD Abs. ±% RSD IRB ATR 
Abs.*± % RSD 
IRB ATR 
   05    05 0.372±0.45 0.266±0.57 
15 15 1.211±0.21 0.884±0.92 
30 30 2.763±0.52 1.877±0.23 
 
Interdayprecision 
The precision of the developed method was assessed by analyzing 
combined standard solution  containing three different  
 
 
concentrations   05, 15, 30  μg/ml  for IRB and 05, 15, 30  μg/ml  ATR 
triplicate (n=3) per day for consecutive 3 days for inter-day 









               Abs.* ±% RSD 
±% RSD Abs. 




 05   05 0.377±0.55 0.270±0.56 
15 15 1.215±0.25 0.887±0.17 




tic mixture at threelevel (80%, 100%, 120%)of standard addition. 
The% recoveryvalues aretabulated in Table 4and 5 
PercentagerecoveryforIRBandATRbythismethodwasfoundinthera
nge of100.07 to 100.43% and99.21 to 100.55%, respectively, 
Thevalueof%RSDwithinthelimitindicatedthatthemethodisaccurate
and percentagerecoveryshows that thereis no interferencefrom 
theexcepients. 
 




Amount of Std.IRB 
added (µg/ml) 
Total amount of IRB 
(µg/ml) 





% RSD IRB 
8        6.4  14.4 12.81±0.022 100.07% 0.32% 
8       8.0 16.6 16.07±0.013 100.43% 0.68% 
8       9.6 17.6 19.22±0.045 100.10% 0.28% 
 




Amount of Std.ATR 
added (µg/ml) 
Total amount of ATR 
(µg/ml) 
Total amount ofATR 
found (µg/ml)* 
Mean± SD 
% Recovery (n=3) % RSD ATR 
       1 0.8 1.8 1.81±0.021 100.55%   0.84% 
       1 1.0 2.0 2.00±0.036 100.50% 0.22% 
       1 1.2 2.2 2.19±0.20 99.21% 0.35% 
 
 
Limit of detection and quantitation TheLODforIRBandATRwasconformedtobe0.033µg/mland0.125µg
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 TheobtainedLODandLOQresults arepresentedin Table 6 
               
Table 6LOD andLOQ dataofIRB andATR *(n=10) 
Conc. (μg/ml) Avg.abs* ± SD % RSD Avg.abs*±SD % RSD 
(226.00nm) IRB (246.00nm) ATR 
IRB ATR   ATR 
5 5 0.371 ±0.0007 1.93 0.270 ±0.0006 0.45 
LOD (μg/ml) 0.033 0.125 
LOQ (μg/ml) 0.1008 0.3792 
Robustness and Ruggedness 
The obtained Ruggedness and Robustness results are presented in table 6.3.8 
The % R.S.D was found to be 0.12 – 0.84 % for IRB and 0.11 – 0.74 % for ATR.  
These %RSD value was found to be less than ± 2.0 indicated that the method is precise. 
No  significant  changes  in  the  spectrums  were  observed,  proving  that  the developed method is rugged and robust. 
 









Preparation   
UV-2450 UV-1800 Stock-1* Stock-2* 
Irbesartan 
Mean (n=3) 
 ± % RSD  
   05 0.376±0.32 0.374±0.47 0.376±0.12 0.373±0.82 
15 1.215±0.56 1.216±0.22 1.215±0.42 1.216±0.56 
30 2.763±0.23 2.765±0.84 2.764±0.21 2.763±0.32 
Atorvastatin 
Mean(n=3)  
 ± %RSD  
   05 0.271±0.54 0.269±0.43 0.272±0.42 0.270±0.11 
15 0.885±0.66 0.882±0.33 0.884±0.15 0.885±0.33 
30 1.879±0.16 1.878±0.13 1.882±0.52 1.884±0.74 
 
   Stock-1 :- 10 mg dissolve in 100 ml Methanol 
  Stock-2 :-  50 mg dissolve in 250 ml Methanol 
APPLICATION OF THE PROPOSED METHOD FOR ANALYSIS OF 
IRB AND ATR IN COMBINED CAPSULE DOSAGE FORM. 
All the excipients were mixed in 10ml volumetric flask and sonicate 
for 15min. make up the volume with Distilled Water. The solution 
was filtered through Whatman filter paper No. 42. 
Finally the solution had concentration 1600μg/ml for IRB and 
200μg/ml for ATR. from that pipette out 0.1ml in 10 ml volumetric 
flask and volumewasmadeuptomarkwithmethanol 
toobtainfinalsolutioncontaining16µg/mlofIRB and 2µg/ml ofATR. 




andATR,respectively.The concentrations of IRB and ATR in 
formulation were determinedusing thecorresponding 
calibrationgraph. 
 
Table 8 Analysisdata ofcommercial formulation*(n=3) 
Sr. No Drug Formulation (μg /ml) % Assay* ± SD USP limit(%) 
1 IRB 16.0 99.75 ± 0.22 98-102% 
2 ATR 2.0 99.52 ± 0.56 98-102% 
 
SUMMARY OF VALIDATION PARAMETER 
Table 9 Summary of validation parameters 
SR. NO.  PARAMETER Irbesartan Atorvastatin 
1  Wave length Max.  226.00 nm 246.00 nm 
2  Linearity  (µg/ml) (n=6)  5 to 30 µg/ml 5 to 30 µg/ml 
3  Regression equation  y = 0.0983x - 0.2385 y = 0.0642x - 0.0695 
4  Correlation coefficient (r
2
)  0.9994 0.9993 
5 Accuracy(%Recovery) (n=3) 100.26 100.13 
6               Precision  
Intra-day (%RSD)(n=3)  







7 LOD  (µg/ml)   (n=10)  0.033 0.125 
8 LOQ (µg/ml)  (n=10)  0.1008 0.3792 
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9 Robustness and Ruggedness     (%RSD) 0.12-0.84 0.11-0.73 
10 Assay       99.75±0.22 99.52 ±0.56 
 
CONCLUSION 
A new, Simultaneous Equation method has been developed for 
estimation of Irbesartan and Atorvastatin in synthetic mixture. The 
method was validated by employment of ICH(18) guidelines. The 
validation data is indicative of good precision and accuracy, and 
prove the reliability of the method. 
REFERANCE 
1. Asif H, Sabir AM and Parminder SB. A review of 
pharmacological and pharmaceutical profile of Irbesartan. 
Pharmacophore. 2(6); 2011:276-86. 
2. Irbesartan drug info in drugbank. (database available on 
internet): http://www.drugbank.ca/drugs/db01029 
3. Irbesartan drug info. (database available on internet): 
http://en.wikipedia.org/wiki/irbesartan 
4. Dileep N, Siva P, Santhi K and Sajeeth C. A review on 
atorvastatin co administration with ezetimibe for the treatment 




5. Atorvastatin drug info in drugbank. (database available on 
internet): http://www.drugbank.ca/drugs/db01076 
6. Virani P, Sojitra R, Raj H and Jain V. A review on Irbesartan co 
administered with Atorvastatin for the treatment of cardiac 
risk. J Crit Rev. 1(1); 2014: 25-28. 
7. Antonio C, Roberta A, Roberto D. et al. Effect of atorvastatin and 
Irbesartan, alone and in combination, on postprandial 
endothelial dysfunction, oxidative stress, and inflammation in 
type 2 diabetic patients. Circulation-American Heart 
Association. 111; 2013:2517-24. 
8. Virani P, Sojitra R, Raj H and Jain V. Irbesartan: A review on 
analytical method and its determination in pharmaceuticals 
and biological matrix.Inventi Rapid: Pharm Analysis & Quality 
Assurance.4; 2014: 1-6. 
9. Virani P, Sojitra R, Raj H and Jain V. Atorvastatin: A review on 
analytical method and its determination in pharmaceuticals 
and biological matrix.Inventi Rapid: Pharm Analysis & Quality 
Assurance. 4; 2014: 1-6. 
10. Virani P, Raj H, Jain V and Jain P. Updated review: validation 
and method validation parameters. Pharmatutor. 2(10); 2014: 
27-37. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
